Performance of a vancomycin dosage regimen developed for obese patients

American Journal of Health-System Pharmacy

Volumn 69, Issue 11, 2012, Pages 944-950

  Reynolds, David C ^a   Waite, Laura H ^b   Alexander, Donald P ^c   DeRyke, C Andrew ^d  

^a MOSES H CONE MEMORIAL HOSPITAL   (United States)

^b ORLANDO HEALTH   (United States)

^c UNIVERSITY OF UTAH HOSPITAL   (United States)

^d Optimer Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; VANCOMYCIN;

ARTICLE; BODY MASS; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG WITHDRAWAL; HUMAN; KIDNEY FUNCTION; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; NEPHROTOXICITY; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84861462800     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110324     Document Type: Article

References (24)

1. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health-Syst Pharm. 2009; 66:82-98.
2. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol. 1998; 54:621-5. (Pubitemid 28531423)
3. Blouin RA, Bauer LA, Miller DD et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982; 21:575-80. (Pubitemid 12070524)
4. Vance-Bryan K, Guay DR, Gilliland SS et al. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother. 1993; 37:436-40. (Pubitemid 23072585)
5. Leong JV, Boro MS, Winter ME. Determining vancomycin clearance in an overweight and obese population. Am J Health-Syst Pharm. 2011; 68:599-603.
6. Moise-Broder PA, Forrest A, Birmingham MC et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004; 43:925-42. (Pubitemid 39447034)
7. DeRyke CA, Alexander DP. Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentration-time curve/minimum inhibitory concentration. Hosp Pharm. 2009; 44:751-65.
8. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report (Sept 1998). www.nhlbi.nih.gov/guidelines/obesity (accessed 2012 Jan 9).
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16:31-41.
10. Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm. 1974; 8:650-5.
11. Reichley RM, Ritchie DJ, Bailey TC. Analysis of various creatinine clearance formulas in predicting gentamicin elimination in patients with low serum creatinine. Pharmacotherapy. 1995; 15: 625-30.
12. Smythe M, Hoffman J, Kizy K et al. Estimating creatinine clearance in elderly patients with low serum creatinine concentrations. Am J Hosp Pharm. 1994; 51:198-204. (Pubitemid 24037798)
13. Jeffres MN, Isakow W, Doherty JA et al. Predictors of mortality for methicillinresistant Staphylococcus aureus healthcare-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest. 2006; 130:947-55. (Pubitemid 44583720)
14. Patel N, Pai MP, Rodvold KA et al. Vancomycin: we can't get there from here. Clin Infect Dis. 2011; 52:969-74.
15. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit. 1994; 16:513-8. (Pubitemid 24296745)
16. Alexander JK, Dennis EW, Smith WG et al. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc Res Cent Bull. 1962-63; 1:39-44.
17. Naeye RL, Roode P. The size and numbers of cells in visceral organs in human obesity. Am J Clin Pathol. 1970; 54:251-3.
18. Rybak MJ, Albrecht LM, Boike SC et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990; 25:679-87. (Pubitemid 20167292)
19. Wong-Beringer A, Joo J, Tse E et al. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents. 2011; 37:95-101.
20. Lodise TP, Patel N, Lomaestro BM et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009; 49:507-14.
21. Lodise TP, Lomaestro B, Graves J et al. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008; 52:1330-6. (Pubitemid 351521995)
22. Hidayat LK, Hsu DI, Quist R et al. High-dose vancomycin therapy for methicillinresistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006; 166:2138-44. (Pubitemid 44631403)
23. Ingram PR, Lye DC, Tambyah PA et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2008; 62:168-71. (Pubitemid 351865892)
24. Jeffres MN, Isakow W, Doherty JA et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007; 29:1107-15. (Pubitemid 47208584)